Ponazuril

Ponazuril
Clinical data
Routes of; administration	Oral
ATCvet code	QP51AJ04 (WHO) ;
Legal status
Legal status	US: ℞-only; Veterinary use only;
Identifiers
	IUPAC name 1-Methyl-3-[3-methyl-4-[4-(trifluoromethylsulfonyl)phenoxy]phenyl]-1,3,5-triazinane-2,4,6-trione;
CAS Number	69004-04-2;
PubChem CID	3050408;
UNII	JPW84AS66U;
CompTox Dashboard (EPA)	DTXSID7048958 ;
ECHA InfoCard	100.157.907
Chemical and physical data
Formula	C18H14F3N3O6S
Molar mass	457.380 g/mol g·mol−1
	(verify)

Ponazuril (INN), sold by the Bayer Corporation under the trade name Marquis, is a drug currently approved for the treatment of equine protozoal myeloencephalitis in horses, caused by Sarcocystis neurona. More recently, veterinarians have been preparing a formulary version of the medication for use in small animals such as cats and dogs against coccidia, an intestinal parasite. Coccidia treatment is far shorter than treatment for EPM.

See also